Solid Tumors Clinical Trial
Official title:
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Verified date | August 2019 |
Source | Peking University First Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Taxanes are one of the most active agents in the treatment of many kinds of solid tumors,
mainly including paclitaxel and docetaxel. However, variability in toxicity and response
remains a major problem for patients receiving taxanes. It is general that there are many
factors for individual differences of drugs in clinical application, of which genetic factors
accounted for more than 20%. Toxicities of docetaxel, such as myelosuppression, neurotoxicity
or mucositis, were evaluated for possible relationship with pharmacogenetic polymorphisms in
several candidate gene and genome-wide association studies. Due to the levels of evidence of
those studies are low and lack of sufficient research data of Chinese, it has the important
significance in studying individual differences of docetaxel in toxicities, through the
pharmacogenomics research.
The aim of this study is to evaluating the association genetic polymorphisms with
docetaxel-based chemotherapy toxicities in chinese solid tumor patients. By detecting the
gene polymorphism, investigators intend to study the pharmacokinetic/pharmacogenomics (PK-PG)
correlation of docetaxel and provide scientific basis for precise medication guide for people
to use docetaxel.
Status | Active, not recruiting |
Enrollment | 2200 |
Est. completion date | December 2019 |
Est. primary completion date | September 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Any native Chinese men or women at least 18 years of age; - Sign informed consent of the research; - Have a histologic or cytologic diagnosis of solid tumor; - Will receive docetaxel-based chemotherapy; Or patients who received docetaxel chemotherapy meet the inclusion and exclusion criteria of the research, and their clinical information is complete to obtain; - Male and female patients with reproductive potential must use an approved contraceptive method during and for 3 months after discontinuation of study treatment. Women with childbearing potential must have a negative pregnancy test within 7 days prior to study enrollment; - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. - Have discontinued all previous therapies for cancer for at least 28 days prior to study entry, and have recovered from the acute effects of therapy. - Have adequate organ function, including: 1. Bone marrow reserve: 1. ANC=1.5×109/L 2. PLT=100×109/L 3. HGB=10g/dL 2. Hepatic: 1. Bilirubin = 1.5ULN 2. ALT, AST =2.5 ULN, =5ULN when liver metastases are known 3. Renal: Src =1.5mg/dl - Electrolytes: Patients may be entered into the study if, in the investigators' opinion, any electrolyte disorders, including K<3.4mEq/L, Ca<8.4mEq/L, or Mg<1.2mEq/L, may be appropriately managed and stabilized by the time of the laboratory evaluation prior to the chemotherapy. If electrolytes have not been stabilized during this time, the patient will be discontinued from the study. - Have an estimated life expectancy, in the judgment of the investigator, which will permit the patient to complete the PK phase and at least 2 cycle of the evaluation of the toxicities. Exclusion Criteria; - Serious concomitant systemic disorder, including active infection, which is incompatible with the study (at the discretion of the investigator). - History of human immunodeficiency virus, hepatitis B, or hepatitis C infections. - Cardiac: Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV. It is recommended that patients with arrhythmias (persistent or paroxysmal ventricular or supraventricular arrhythmias, including atrial fibrillation or bradycardia (heart rate <50 beats per minute))be excluded at the investigator's discretion. - Known family history of unexplained sudden death. - Personal history of unexplained syncope within the last year. - Women who are breast feeding, lactating, or pregnant. - Patients with known allergies to docetaxel and its supplementary materials. - Drugs and herbal supplements that are known to be potent or moderate inhibitors or inducers of cytochrome P450 (CYP)3A4 are specifically excluded. Foods that are known to be potent or moderate inhibitors of CYP3A4 are also specifically excluded during the study. - Patients receiving herbal regimens. - Use of drugs with narrow therapeutic windows that are also known substrates of CYP3A4. - Failure for any reason to satisfy the investigator for adequate fitness to participated in the study. |
Country | Name | City | State |
---|---|---|---|
China | Affiliated Hospital of Academy of Military Medical Sciences | Beijing | Beijing |
China | Beijing Cancer Hospital | Beijing | Beijing |
China | Peking University First Hospital | Beijing | Beijing |
China | Fuling Center Hospital of Chongqing City | Chongqing | Chongqing |
China | The First Hospital of China Medical University | Shenyang | Liaoning |
China | The FIrst Affiliated Hospital of Wenzhou Medical University | Wenzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Cui Yimin |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of severe hematological toxicity | The toxicity induced by docetaxel-based chemotherapy during observation time will be estimated on the basis of the National Cancer Institute Common Toxicity Criteria Version 4.03. Patients with grade 3-4 adverse events will be considered as having severe toxicity. At the end of each cycle (each cycle is 21 days) the grade will be scored. And the severest grade will be recorded and used for analysis. Hematological toxicity includes neutropenia, leukopenia, anemia and thrombocytopenia. | At 1 year | |
Secondary | Incidence of other severe toxicities | The other toxicities induced by docetaxel-based chemotherapy during observation time, including gastrointestinal toxicity, neurotoxicity etc., will be estimated on the basis of the National Cancer Institute Common Toxicity Criteria Version 4.03. Toxicities with grade 3-4 will be considered as severe toxicity, except for severe neurotoxicity (grade 2-3). At the end of each cycle (each cycle is 21 days) the grade will be scored. And the severest grade will be recorded and used for analysis. | At 1 year | |
Secondary | Genotyping | Collect blood specimen, then detect genotype by next generation sequencing. | Before chemotherapy | |
Secondary | The kinds of the metabolites | Determine the metabolic profiles of docetaxel. This outcome is not applicable to patients retrospectively collected. | Pre-dose and 6 hours post-dose in the first cycle | |
Secondary | Area under the curve [AUC] | Determine the AUC of docetaxel and its metabolites. This outcome is not applicable to patients retrospectively collected. | Pre-dose and 6 hours post-dose in the first cycle |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |